This 2013 JAAOS review by Raskin et al. covers the pathology, staging, imaging, and treatment of giant cell tumor (GCT) of bone. It addresses which cell type drives the disease, how to grade lesions radiographically, and how surgical and adjuvant choices affect recurrence risk. Medical therapies including bisphosphonates and denosumab are also reviewed.
A 20-35 year-old presents with pain and swelling around the knee or wrist, and plain films show a purely lytic epiphyseal lesion without a sclerotic rim. GCT is at the top of your differential. Get MRI, bone scan, and chest imaging before biopsy — biopsy first will distort your ability to define the local extent of disease.
For most cases, extended intralesional curettage with adjuvant therapy is appropriate. Curettage alone leaves a 45% recurrence risk; adding phenol, hydrogen peroxide, or cement brings this to 17%. Cryosurgery is the most effective adjuvant (<8% recurrence) but carries real fracture and vascular injury risk.
For axial or surgically inaccessible disease, denosumab is your best medical option. 86% tumor response in phase 2 data. Megavoltage radiation is a reasonable alternative for sacral or inoperable lesions, with <1% malignant transformation risk and 85% 10-year progression-free survival.
Remember: pathologic fracture through a GCT does not worsen oncologic outcomes, so if the joint is congruent, it is reasonable to let the fracture heal before operating.
This 2013 JAAOS review by Raskin et al. covers the pathology, staging, imaging, and treatment of giant cell tumor (GCT) of bone. It addresses which cell type drives the disease, how to grade lesions radiographically, and how surgical and adjuvant choices affect recurrence risk. Medical therapies including bisphosphonates and denosumab are also reviewed.
A 20-35 year-old presents with pain and swelling around the knee or wrist, and plain films show a purely lytic epiphyseal lesion without a sclerotic rim. GCT is at the top of your differential. Get MRI, bone scan, and chest imaging before biopsy — biopsy first will distort your ability to define the local extent of disease.
For most cases, extended intralesional curettage with adjuvant therapy is appropriate. Curettage alone leaves a 45% recurrence risk; adding phenol, hydrogen peroxide, or cement brings this to 17%. Cryosurgery is the most effective adjuvant (<8% recurrence) but carries real fracture and vascular injury risk.
For axial or surgically inaccessible disease, denosumab is your best medical option. 86% tumor response in phase 2 data. Megavoltage radiation is a reasonable alternative for sacral or inoperable lesions, with <1% malignant transformation risk and 85% 10-year progression-free survival.
Remember: pathologic fracture through a GCT does not worsen oncologic outcomes, so if the joint is congruent, it is reasonable to let the fracture heal before operating.